Company / Cash & Equivalents
Ginkgo Bioworks Holdings, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$167.2M
FY2025
5-year range
$167.2M / $1.6B
FY2021-FY2025
Trend
-70.2%
vs FY2024
Sector context
#107 of 209
Health Care
What the data says
At $167M, Ginkgo Bioworks Holdings, Inc.'s cash & equivalents ranks #107 of 209 in the Health Care sector. Cash & Equivalents has declined for 4 consecutive years, from $1.6B in FY2021 to $167M in FY2025.
Based on SEC 10-K filings.
$167M in FY2025 with a 5-year CAGR of -15.2%.
Declined from $944M to $167M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -49.7%
- 5-Year CAGR
- -15.2%
- 10-Year CAGR
- -
Sector benchmark
#107 of 209 in Health CareTop 51% of 209This company $167.2M Sector average $696.0M
▼
-76.0% below sector average
Key checks
Key Insights
- Ginkgo Bioworks Holdings, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -15.2%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 70.2% year-over-year.
- Ranks #107 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $167.2M | -70.2% |
| FY2024 | $561.6M | -40.5% |
| FY2023 | $944.1M | -28.3% |
| FY2022 | $1.3B | -15.1% |
| FY2021 | $1.6B | +307.0% |
| FY2020 | $380.8M | -23.1% |
| FY2019 | $495.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026